Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-775P is a pseudogene copy of the U6 small nuclear RNA gene. U6 snRNA is a highly conserved, essential component of the spliceosome and participates in pre-mRNA splicing, but RNU6-775P itself is classified as a pseudogene, meaning it is a nonfunctional homolog derived from the original gene and does not produce a functional RNA or protein[1][4]. Pseudogenes such as RNU6-775P are prevalent in the genome, often arising via duplication or retrotransposition events, and in most cases lack any known biological activity[2]. Although some pseudogenes have been found to be transcribed and can act as regulatory RNA molecules influencing gene expression or disease processes, there is no evidence that RNU6-775P possesses such activity or is involved in any known physiological or pathological roles[1][2]. Additional notes: - RNU6-775P is not a protein-coding gene, enzyme, transporter, or receptor, nor is it used as a therapeutic target. - Its sequence is annotated as small nuclear RNA (snRNA) pseudogene, not as an active U6 snRNA[4][1]. - While the parental U6 snRNA has critical biological functions, this pseudogene does not share those functions and should not be conflated with the functional U6 snRNA[5][3]. Interpretive Guidance: - RNU6-775P is not an active molecular target or therapeutic target; it is a genome-embedded relic of U6 snRNA with no established function[1][4]. - No interacting drugs, biomarker roles, or mechanism of action information is applicable. - The entry is "incorrect" in the sense that it is not a viable therapeutic target, protein, receptor, or enzyme, and has no established utility or function related to disease or pharmacology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 775, pseudogene (RNU6-775P).